Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

ODM service for ergonomic pillows Thailand

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Ergonomic insole ODM production factory Taiwan

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Taiwan insole ODM design and production

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Pillow ODM design company in Taiwan

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.Thailand neck support pillow OEM

Computer-rendered image showing T cells (red) interacting with monocytes (yellow) and dendritic cells (blue) in the tumor microenvironment. These interactions help T cells to fully mature and effectively target and kill cancer cells. The scale bar (white) represents 10 micrometers (µm), indicating the size of the tumor regions shown. Credit: IMP Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to potential strategies to enhance treatment efficacy and overcome resistance. Immunotherapy has transformed cancer treatment, providing new hope for cancers once deemed incurable by harnessing the immune system to fight the disease. However, many cancers can evade immune attacks, leading to resistance against these treatments. Researchers led by Anna Obenauf at the IMP have identified a critical role for inflammatory monocytes—an immune cell type—in reactivating T cells to attack cancer cells within tumors. Published in Nature, these findings position monocytes as a promising target to enhance immunotherapy, with the potential to benefit patients battling cancers such as melanoma, lung, pancreatic, and colorectal cancer. The Evolution of Immunotherapy Over the past few decades, immunotherapy has revolutionized cancer treatment, providing effective options for diseases once thought to be untreatable, including melanoma, lung cancer, and bladder cancer. What began as experimental research in laboratories has now transitioned into life-changing clinical applications, offering new hope for patients with difficult-to-treat conditions. How Immunotherapy Works Immunotherapy works by utilizing the body’s immune system to target and destroy cancer cells. This is achieved either by broadly boosting immune activity or by focusing on specific pathways that help the immune system recognize, attack, and eliminate cancer cells. Despite its significant advancements, immunotherapy still faces major challenges. A key obstacle is cancer’s ability to evade the immune system by altering its cells to escape detection and creating an immune-suppressive environment within the tumor. As a result, many patients do not respond to current treatments—for instance, more than 50% of those diagnosed with melanoma, the most aggressive type of skin cancer, see limited or no benefit. Advanced Research in Cancer Immunotherapy Much of how cancer evades the immune response remains unknown, largely due to the complex cascade of molecular events in the interactions between cancer and immune cells. Understanding the nuances of these processes will be key to developing more effective therapies. In a study led by Anna Obenauf, Senior Group Leader at the IMP, an international team of researchers integrated cutting-edge tools, including melanoma mouse models, single-cell RNA sequencing, and advanced functional genetics and imaging technologies, to push the boundaries of our understanding of the immune system’s role in fighting cancer. The study, now published in the journal Nature, reveals an additional type of immune cell involved in stimulating the immune response against cancer, opening up possibilities for new strategies to boost immunotherapy and potentially expand its benefits to more patients. Rethinking the Cancer Immunity Cycle Researchers studying the body’s antitumor defenses often refer to the ‘cancer immunity cycle’—a series of steps through which immune cells recognize and eliminate cancer cells. At the core of this cycle are T cells, the immune system’s primary cancer-fighting cells. But T cells do not work alone; they rely on activation from other immune cells, particularly antigen-presenting cells (APCs) such as dendritic cells–the main T cell activators. The process begins when cancer cells release protein fragments, or antigens, that are captured by APCs. These cells present the antigens to T cells, effectively ‘priming’ them to recognize cancer cells as targets. Once activated in the lymph nodes, T cells travel to the tumor site to destroy it, releasing new antigens that restart the cycle of immune activation. “The cancer immunity cycle, as we understand it today, is actually incomplete—we’re missing the crucial step of T cell reactivation within the tumor microenvironment,” says Anais Elewaut, co-first author of the study and a student in the Vienna BioCenter PhD Program. “We discovered that when T cells reach the tumor, they still need additional activation from other immune cells to be fully effective.” Novel Findings and Future Directions To identify the missing components in this process, the scientists used powerful cell models to investigate the factors that make cancer susceptible to the most common immunotherapies. Two melanoma cell line models derived from mice that respond differently to commonly used therapies were generated at the Obenauf lab: one that responds well to both immunotherapy and targeted therapy, which applies substances aimed at specific cancer cells; the other resistant to both these treatment types. “With this system, we could closely compare responsive to resistant tumors, helping us figure out the key factors that determine whether a treatment will succeed or fail.” Monocytes: A New Player in Cancer Immunity The team first analyzed the tumor environment in both models by profiling gene expression at the level of single cells, and then sorted and quantified immune cell types based on specific markers on their surface. “We were very interested when we noticed lots of monocytes in responsive tumors compared to resistant ones. Monocytes are a type of immune cell never reported to play a role in T cell stimulation,” explains Elewaut. For the longest time, researchers had been looking at dendritic cells as the main activators of T cells, overlooking the role of other immune cells. In contrast, the resistant model had few monocytes, but was filled with suppressive macrophages, which are known to inhibit immune responses.   “Monocytes were thought to play a limited role in cancer immunity,” explains Guillem Estivill, co-first author of the study and a student in the Vienna BioCenter PhD Program. “Now we show how the presence or absence of these specific immune cells can lead to very different treatment outcomes.” Whereas dendritic cells are critical for kickstarting the cancer immunity cycle in the lymph node, both dendritic cells and monocytes are needed to fully activate T cells in the tumor. The scientists found that monocytes can directly ‘borrow’ parts of cancer cells, including antigens, and present them to T cells. This process, called ‘cross-dressing’, allows monocytes to reactivate T cells, which boosts their function in recognizing and attacking cancer cells. Diagram showing how inflammatory monocytes help reactivate T cells, and how the molecules PGE2 and IFN-I work together to create an inflammatory tumour environment, support T cell activation, and immunotherapy response. Credit: IMP Restoring Immune Balance Against Cancer The study also shows how cancer cells evade immunity by making it harder for T cells to stay activated and perform effectively. Cancer cells increase production of the molecule prostaglandin E2, which blocks the action of both monocytes and dendritic cells. Simultaneously, cancer cells decrease the production of interferons—molecules that stimulate immune activity— thereby further weakening the immune system’s ability to fight the tumor. “We’ve seen that restoring the levels of these molecules brings T cells back to their cancer-killing action through the activation of monocytes,” explains Estivill. Building on this discovery, one promising strategy will be to use COX inhibitors, such as aspirin—drugs that block the cyclooxygenase (COX) enzyme, which is responsible for producing molecules that cause inflammation such as prostaglandin E2. Additionally, stimulating interferon production could enhance the immune system’s ability to combat cancer. These approaches could be combined with existing immunotherapies, providing new tools against cancers that are currently resistant to treatment. The findings make monocytes promising targets to boost immunotherapies, with insights that have the potential to benefit a wide range of patients affected by cancers with similar molecular pathways to melanoma. These include lung, pancreatic, and colorectal cancer. Future Directions in Immunotherapy Future research will focus on exploring how stimulating T cells with monocytes and other immune cells plays out in different forms of immunotherapy. This knowledge could reveal new ways to overcome resistance to immunotherapies. “Clinical trials combining COX inhibitors and immunotherapy are on the horizon. And we already identified strategies to enhance their effectiveness,” says Anna Obenauf. “Our goal is to deepen the mechanistic understanding of anti-tumor immunity. I hope this will help us overcome resistance in more patients, making cancer immunotherapy a viable option for a broader range of patients.” Reference: “Cancer cells impair monocyte-mediated T cell stimulation to evade immunity” by Anais Elewaut, Guillem Estivill, Felix Bayerl, Leticia Castillon, Maria Novatchkova, Elisabeth Pottendorfer, Lisa Hoffmann-Haas, Martin Schönlein, Trung Viet Nguyen, Martin Lauss, Francesco Andreatta, Milica Vulin, Izabela Krecioch, Jonas Bayerl, Anna-Marie Pedde, Naomi Fabre, Felix Holstein, Shona M. Cronin, Sarah Rieser, Denarda Dangaj Laniti, David Barras, George Coukos, Camelia Quek, Xinyu Bai, Miquel Muñoz i Ordoño, Thomas Wiesner, Johannes Zuber, Göran Jönsson, Jan P. Böttcher, Sakari Vanharanta and Anna C. Obenauf, 27 November 2024, Nature. DOI: 10.1038/s41586-024-08257-4 Guillem Estivill is a PhD student in Anna Obenauf’s lab at the IMP and a member of the EVOMET network, a renowned European consortium dedicated to studying the evolution of cancer metastasis. Supported by the European Commission’s Innovative Training Networks program under the Marie Skłodowska-Curie Actions, EVOMET is coordinated by the Institute for Research in Biomedicine (IRB) Barcelona and includes thirteen leading academic, clinical, and industrial institutions. This collaborative initiative trains early-career researchers in metastasis biology and therapeutic development. By promoting interdisciplinary and cross-sector collaboration, EVOMET aims to fast-track the development of targeted therapies and improve treatments for metastatic cancer.

A new study that centered on the swimming behavior of sperm cells is the first to establish a direct effect of mutation on sperm behavior. It suggests that the development and application of screens based on sperm behavior can improve the quality of the genetics they carry. Research offers additional insights into the reproductive process. A team of scientists has discovered that the behavior of sperm cells is due, in part, to the individual DNA makeup of these cells, rather than only the genetics of males. These results, which provide a new understanding of the competition among sperm cells to fertilize the egg, have larger implications for the reproductive process. The study, which centers on the swimming behavior of sperm cells, is the first to establish a direct effect of mutation on sperm behavior and suggests that the development and application of screens based on sperm behavior can improve the quality of the genetics they carry. Male Astyanax mexicanus (blind cave fish). Credit: Richard Borowsky, New York University “Until now, the predominant view was that this variation in swimming behavior reflected the overall genetics of the male rather than the variable genetics of the individual sperm cells,” explains Richard Borowsky, a professor emeritus in NYU’s Department of Biology and the senior author of the paper, which will be published today (November 11) in the journal Scientific Reports. “This study is the first to demonstrate that genetic differences can directly affect the swimming behavior of sperm cells.” Abnormal Sperm Cells and Reproduction This fuller grasp, he adds, may offer additional knowledge on the impact of abnormal sperm cells on offspring, notably birth defects. The work, which included Haining Chen, an NYU graduate student at the time of the study and now at Westlake University in Hangzhou, China, focused on sperm cells in male fish—specifically Astyanax mexicanus cave fish. It compared the sperm cells in normal fish with those of fish whose sperm production had been artificially mutated. This allowed the scientists to identify behavioral and morphological characteristics potentially altering the sperm’s chances in the race to fertilize the egg. Paths of individual swimming sperm over a one-second interval, illustrating the great variation among individual sperm in swimming velocity and curvature. Credit: Richard Borowsky, New York University Sperm Swimming Speed and Variability Their results showed no difference in flagellar length— the hair-like appendage that propels them as they swim toward the egg—between the normal and mutated samples. However, there was greater variability in the velocity, or swimming speed, of the mutated samples compared to the normal ones—meaning that in many instances, the mutated samples swam at lower and faster speeds than the normal ones did. Overall, while both types of sperm cells appeared similar, their behaviors are quite different and at crucial stages. The findings offer additional insights into the nature of reproduction. It’s been long established that sperm from different males vary in their characteristics because of the genetic differences between the males. This study established that different sperm from the same male vary in their characteristics because they differ in their genetic cargo. Reference: “Mutagenesis alters sperm swimming velocity in Astyanax cave fish” by Richard Borowsky and Haining Chen, 15 November 2022, Scientific Reports. DOI: 10.1038/s41598-022-22486-5

‘Extinct’ houting from the collection of the Natural History Museum London. Credit: Ymke Winkel The houting fish, once thought extinct, is still thriving, as revealed by DNA comparisons with the European whitefish by researchers from the University of Amsterdam and the Natural History Museum London. The houting, a fish species that lived in North Sea estuaries and is officially extinct, turns out to be alive and well. Researchers from the University of Amsterdam and the Natural History Museum London extracted DNA from multiple houtings conserved in the museum, up to 250+ years old. Next, they compared the DNA of these museum fish with DNA from various currently occurring sibling species. The biologists found hardly any genetic difference between houting and a species called European whitefish. Since this species is still common, houting also isn’t extinct. DNA Research and Findings In a study that was recently published in the journal BMC Ecology and Evolution, the scientists describe how they isolated mitochondrial DNA from the fish. They even managed to obtain a small piece of DNA from a dried North Sea houting from 1754 that was used by Linnaeus for the official species description. Next, the researchers used the DNA to create a phylogenetic tree, in which all examined houting (Coregonus oxyrinchus) ended up in the same group as the European whitefish (Coregonus lavaretus). Not Extinct According to the research team, houting is therefore not a separate species. First author Rob Kroes of the University of Amsterdam comments: “The European whitefish is fairly widespread in Western and Northern Europe, both in freshwater rivers and lakes, estuaries and the sea. Because we found no species difference between houting of the past and today’s European whitefish, we do not consider the houting to be extinct.” External Traits vs. DNA So, how is it possible that the houting was officially declared extinct in 2008? Kroes explains, “It often happens that there is confusion as to whether animals are one species or not. Especially when fish are involved. They often have a lot of variation in morphological traits within a species. In this case, biologists long thought that houting is a different species from the European whitefish due to the length of the snout and the number of gill rakers. But these traits are simply not suitable to say that houting is a different species. Our DNA research now clearly shows that it isn’t.” Impending Name Revision A change of the official Latin species name seems to be in order. However, a definitive adjustment of the name requires a bit of additional research on the DNA of the dried fish from 1754. According to the researchers, this will be difficult to do. Kroes concludes: “The DNA is old and damaged, but I think we should try. At the moment, the protected status of various coregonids is a mess. According to the IUCN, North Sea houting is extinct; at the same time, there are various European nature laws that state that both houting and European whitefish must be protected. So we are actually protecting an extinct species that is just swimming around at the moment.” Reference: “Phylogenetic analysis of museum specimens of houting Coregonus oxyrinchus shows the need for a revision of its extinct status” by R. Kroes, Y. Winkel, J. A. J. Breeuwer, E. E. van Loon, S. P. Loader, J. S. Maclaine, P. F. M. Verdonschot and H. G. van der Geest, 27 September 2023, BMC Ecology and Evolution. DOI: 10.1186/s12862-023-02161-7

DVDV1551RTWW78V